Vivos Therapeutics, Inc. (NASDAQ:VVOS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) have earned an average recommendation of “Hold” from the five research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $4.9167.

A number of analysts have recently issued reports on VVOS shares. Zacks Research upgraded shares of Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, December 1st. Ascendiant Capital Markets reduced their target price on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright initiated coverage on Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 price objective for the company.

Vivos Therapeutics Stock Up 3.3%

NASDAQ VVOS opened at $1.55 on Friday. Vivos Therapeutics has a 52 week low of $1.42 and a 52 week high of $7.95. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31. The business’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $2.99. The firm has a market cap of $14.63 million, a PE ratio of -0.88 and a beta of 6.93.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings data on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. The firm had revenue of $6.78 million during the quarter, compared to analyst estimates of $4.49 million. As a group, equities analysts anticipate that Vivos Therapeutics will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On Vivos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in VVOS. Connective Capital Management LLC purchased a new position in shares of Vivos Therapeutics during the 3rd quarter worth approximately $620,000. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics during the second quarter worth $220,000. Finally, XTX Topco Ltd purchased a new position in shares of Vivos Therapeutics during the second quarter worth $65,000. 26.35% of the stock is owned by hedge funds and other institutional investors.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.